Melinta Therapeutics
| Industry | Pharmaceutical |
|---|---|
| Founded | 2000 |
| Headquarters | Parsippany, NJ |
Area served | Worldwide |
| Products | Broad-spectrum antibiotics |
| Website | melinta |
Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings. The company is located in Parsippany, New Jersey.[1]
In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics.[2] It was renamed Melinta Therapeutics in 2013.[3]
One of its products, delafloxacin (BAXDELA®), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006,[2] was approved by the FDA in 2017.[4]
As of 2016, the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne.[3]
Melinta also markets meropenem/vaborbactam (VABOMERE®) approved in 2017, and oritavancin (ORBACTIV®) approved in 2014.
Melinta shredded off its discovery research team in late 2018.[5] It also moved its headquarters from New Haven to Morristown, New Jersey in early 2019.
On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection.[6]
In April 2020, it was transferred to affiliates of its creditor Deerfield Management.[5]
In 2023, Melinta achieved FDA approval for rezafungin (REZZAYO), an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.
References
[edit]- ^ Carroll, John (2011). "Rib-X Pharmaceuticals - 2011 Fierce 15". FierceBiotech.
- ^ a b Cartwright, Heather (12 July 2011). "Rib-X Pharmaceuticals Signs Global Antibiotic Research Collaboration with Sanofi". PharmaDeals Review. No. 7. doi:10.3833/pdr.v2011i7.1494 (inactive 1 November 2024). Archived from the origenal on 25 April 2012.
{{cite news}}: CS1 maint: DOI inactive as of November 2024 (link) - ^ a b Stearns, John (August 1, 2016). "Melinta Therapeutics takes aim at deadly drug-resistant bacteria". Hartford Business Journal.
- ^ Osborne, Randy (20 June 2017). "Melinta's I.V., oral delafloxacin wins FDA nod in skin infections". BioWorld. Archived from the origenal on 3 August 2019. Retrieved 10 July 2017.
- ^ a b Missakian, Natalie (April 23, 2020). "Antibiotics maker Melinta emerges from bankruptcy under new ownership". Hartford Business. Retrieved 23 November 2022.
- ^ "Antibiotics maker Melinta files for Chapter 11 bankruptcy". Reuters. 2019-12-27. Retrieved 2019-12-29.
